ArticleJournal of the American Society of Nephrology : JASN2021
AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.
2 registry-linked trialsAbstract readMulticenter Study
In one paragraph
Article in Journal of the American Society of Nephrology : JASN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 171 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 7 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19
Prospective Observational Study Examining Clinical Characteristics, Inflammatory Markers, Treatments and Outcomes of Patients Hospitalized for COVID-19 at the University of Michigan Healthcare System in Ann Arbor
Who cites it
171 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Health inequalities and outcomes following acute kidney injury: a systematic review & meta-analyses of observational studies.BMC nephrology · 2025Pooled it
- Acute kidney injury in patients with COVID-19 compared to those with influenza: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Incidence, risk factors and outcomes of acute kidney injury among COVID-19 patients: A systematic review of systematic reviews.Frontiers in medicine · 2022Pooled it
- Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis.Critical care medicine · 2021Pooled it
- A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity.BMC public health · 2021Pooled it
- Vitamin D supplementation for the treatment of COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2021Pooled it
- Acute kidney injury outcomes in covid-19 patients: systematic review and meta-analysis.Jornal brasileiro de nefrologiaPooled it
- Early Nephrology Consultation and Acute Kidney Injury in Hospitalized Patients: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Standard vs. carbone dioxide adapted kidney replacement therapy in hypercapnic ARDS patients: a randomized controlled pilot trial (BigBIC).Critical care (London, England) · 2024Trial
- Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Trial
- Four-organ SOFA score as a potential tool to triage use of continuous kidney replacement therapy in COVID-19 patients with acute kidney injury: a retrospective two-center study.Renal failure · 2026Article
- Acute and chronic kidney injury following COVID-19 infection and vaccination: a narrative review.European journal of translational myology · 2026Article
- The global epidemiology of acute kidney injury: challenges and opportunities.Nature reviews. Nephrology · 2026Review
- Lupus Nephritis During the COVID-19 Pandemic: Challenges and Implications Before, During, and After.Biomedicines · 2025Article
- Long-term renal consequences of COVID-19. Emerging evidence and unanswered questions.International urology and nephrology · 2025Review
- Long-Term Renal Outcomes Among COVID-19 ICU Survivors Admitted With Acute Kidney Injury.Cureus · 2025Article
- PEEP-AKI-COVID ICU: Effect of positive end-expiratory pressure on acute kidney injury development in patients with COVID-19-associated acute respiratory distress syndrome: an ancillary analysis of the COVID-ICU study.Journal of intensive care · 2025Article
- Kidney involvement and anemia in COVID-19 infection.World journal of nephrology · 2025Review
- Can Biomarkers Predict Kidney Function Recovery and Mortality in Patients with Critical COVID-19 and Acute Kidney Injury?Diagnostics (Basel, Switzerland) · 2025Article
- RECOVID: Retrospective Observational Study of Renal Outcomes and Long-Term Mortality in Patients With COVID-19-Associated AKI, A Comparison Between Vaccinated and Unvaccinated Patients.Kidney medicine · 2025Article
111 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
47 authors.
Shruti GuptaDivision of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-5747-2151
Steven G CocaDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-0928-9168
Lili ChanDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Michal L MelamedDepartment of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.
Samantha K BrennerDepartment of Internal Medicine, Hackensack Meridian School of Medicine, Seton Hall, Nutley, New Jersey.
Salim S HayekDivision of Cardiology, University of Michigan Medical Center, Ann Arbor, Michigan.ORCID 0000-0003-0180-349
Anne SutherlandDivision of Pulmonary and Critical Care Medicine, Rutgers New Jersey Medical School, Newark, New Jersey.
Sonika PuriDivision of Nephrology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Anand SrivastavaDivision of Nephrology and Hypertension, Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Amanda Leonberg-YooRenal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Alexandre M ShehataDepartment of Medicine, Hackensack Meridian Health Mountainside Medical Center, Glen Ridge, New Jersey.
Jennifer E FlytheDivision of Nephrology and Hypertension, Department of Medicine, University of North Carolina Kidney Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Arash RashidiDivision of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Edward J SchenckDivison of Pulmonary and Critical Care Medicine, Department of Medicine Weill Cornell Medicine, New York, New York.
Nitender GoyalDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts.
S Susan HedayatiDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Rajany DyDivision of Pulmonary and Critical Care Medicine, University Medical Center, University of Nevada, Las Vegas, Nevada.
Anip BansalDivision of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Ambarish AthavaleDivision of Nephrology, Cook County Health, Chicago, Illinois.
H Bryant NguyenDivision of Pulmonary, Critical Care, Hyperbaric, Allergy, and Sleep Medicine, Loma Linda University Health, Loma Linda, California.
Anitha VijayanDivision of Nephrology, Washington University, St. Louis, Missouri.
David M CharytanDivision of Nephrology, New York University Grossman School of Medicine, New York, New York.ORCID 0000-0002-7695-3583
Carl E SchulzeDivision of Nephrology, Department of Medicine, University of California, Los Angeles, California.
Min J JooDepartment of Medicine, Section of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois, Chicago, Illinois.
Allon N FriedmanDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Jingjing ZhangDivision of Nephrology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
Marie Anne SosaDivision of Nephrology, Department of Medicine, University of Miami Miller School of Medicine and Jackson Memorial Hospital, Miami, Florida.
Eric JuddDivision of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama.
Juan Carlos Q VelezDepartment of Nephrology, Ochsner Health System, New Orleans, Louisiana.
Mary MallappallilDivision of Nephrology, Kings County Hospital Center, New York City Health and Hospital Corporation, Brooklyn, New York.
Roberta E RedfernResearch Department, ProMedica Research, ProMedica Toledo Hospital, Toledo, Ohio.
Amar D BansalRenal and Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Javier A NeyraDivision of Nephrology, Department of Internal Medicine, Bone and Mineral Metabolism, University of Kentucky, Lexington, Kentucky.
Kathleen D LiuDivision of Nephrology and Critical Care Medicine, University of California, San Francisco, California.
Amanda D RenaghanDivision of Nephrology, University of Virginia Health System, Charlottesville, Virginia.
Marta ChristovDepartment of Medicine-Nephrology, Westchester Medical Center, New York Medical College, New York, New York.
Miklos Z MolnarDepartment of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee.ORCID 0000-0002-9665-330
Shreyak SharmaDivision of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Omer KamalDivision of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Jeffery Owusu BoatengDepartment of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.
Samuel A P ShortUniversity of Vermont Larner College of Medicine, Burlington, Vermont.ORCID 0000-0002-3847-4768
Andrew J AdmonDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Meghan E SiseDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Wei WangDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Chirag R ParikhDivision of Nephrology, Johns Hopkins School of Medicine, Baltimore, Maryland.ORCID 0000-0001-9051-7385
David E LeafDivision of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0001-7875-090
and the STOP-COVID Investigators
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MThe Institute for Translational MedicineUL1TR002389 · NCATS · UNIVERSITY OF CHICAGO · PI Joshua J Jacobs, DAVID O MELTZER · 2017 to 2026
$71.6MNorthwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8MKentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2MNovel Biomarkers in Cardiac Surgery to Detect Acute Kidney InjuryR01HL085757 · NHLBI · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2007 to 2019
$10.3MTherapeutics Development Core (Core B)P30DK114857 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LUO, XUNRONG · 2018 to 2022
$5.7MNatural Language Processing and Automated Speech Recognition to Identify Older Adults with Cognitive Impairment SupplementR01AG066471 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FEDERMAN, ALEX D, WISNIVESKY, JUAN P · 2020 to 2024
$4.5MPlasminogen in glomerular disease progressionR01DK126477 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Kirk N Campbell · 2020 to 2026
$3.8MDeferoxamine for the Prevention of Acute Kidney InjuryR01DK125786 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI LEAF, DAVID EVAN · 2020 to 2024
$3.5MRole of SuPAR in the Intersection between Cardiovascular and Kidney DiseaseR01HL153384 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HAYEK, SALIM · 2020 to 2024
$2.5MImpact of Exercise on Kidney Function and Injury among Elders in the LIFE TrialR01DK115562 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI COCA, STEVEN G, SHLIPAK, MICHAEL G · 2018 to 2020
$2.2MImpact of early antiretroviral therapy on kidney disease outcomesR01DK112258 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WYATT, CHRISTINA M · 2017 to 2021
$2.1MNCATS NIH HHS UL1 TR001422NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1TR001998NCATS NIH HHS UL1 TR002389NHLBI NIH HHS F32HL149337NHLBI NIH HHS K23 HL130648NHLBI NIH HHS K23 HL143053NHLBI NIH HHS R01HL085757NHLBI NIH HHS R01HL144566NHLBI NIH HHS R01 HL153384NHLBI NIH HHS R01HL85757NIA NIH HHS R01AG066471NIDCD NIH HHS F32DC17342NIDDK NIH HHS K23 DK116967NIDDK NIH HHS K23 DK117014NIDDK NIH HHS K23 DK120811NIDDK NIH HHS P30 DK114857NIDDK NIH HHS R01DK112258NIDDK NIH HHS R01DK115562NIDDK NIH HHS R01DK125786NIDDK NIH HHS R01DK126477NIDDK NIH HHS U01DK106962
Abstract
backgroundAKI is a common sequela of coronavirus disease 2019 (COVID-19). However, few studies have focused on AKI treated with RRT (AKI-RRT).
methodsWe conducted a multicenter cohort study of 3099 critically ill adults with COVID-19 admitted to intensive care units (ICUs) at 67 hospitals across the United States. We used multivariable logistic regression to identify patient-and hospital-level risk factors for AKI-RRT and to examine risk factors for 28-day mortality among such patients.
resultsA total of 637 of 3099 patients (20.6%) developed AKI-RRT within 14 days of ICU admission, 350 of whom (54.9%) died within 28 days of ICU admission. Patient-level risk factors for AKI-RRT included CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, higher d-dimer, and greater severity of hypoxemia on ICU admission. Predictors of 28-day mortality in patients with AKI-RRT were older age, severe oliguria, and admission to a hospital with fewer ICU beds or one with greater regional density of COVID-19. At the end of a median follow-up of 17 days (range, 1-123 days), 403 of the 637 patients (63.3%) with AKI-RRT had died, 216 (33.9%) were discharged, and 18 (2.8%) remained hospitalized. Of the 216 patients discharged, 73 (33.8%) remained RRT dependent at discharge, and 39 (18.1%) remained RRT dependent 60 days after ICU admission.
conclusionsAKI-RRT is common among critically ill patients with COVID-19 and is associated with a hospital mortality rate of >60%. Among those who survive to discharge, one in three still depends on RRT at discharge, and one in six remains RRT dependent 60 days after ICU admission.
Indexed as
Critical CareRenal Replacement TherapyAcute Kidney InjuryAdolescentAdultAgedAged, 80 and overCohort StudiesCOVID-19FemaleHospitalizationHospital MortalityHumansIncidenceLogistic ModelsMaleacute kidney injuryacute renal failureclinical epidemiologyCOVID-19dialysisrenal replacement therapyrisk factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04343898ClinicalTrials.gov
NCT04706533ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.